As the president of Novartis AG's Institute for Biomedical Research, James (Jay) Bradner oversees drug discovery and early development at the big pharma, committing resources to going after "high-hanging fruit" in some cases. He built his reputation in part from pioneering work on targeted protein degradation studying targets that are considered undruggable, and he has been an outspoken critic of industry at times for a tendency to chase after the same targets.
As Bradner said in a recent interview at NIBR's Cambridge, MA, headquarters, "I loathe fast follower innovation."







